The FOXO3a Transcription Factor Regulates Cardiac Myocyte Size Downstream of AKT Signaling*

Although signaling mechanisms inducing cardiac hypertrophy have been extensively studied, little is known about the mechanisms that reverse cardiac hypertrophy. Here, we describe the existence of a similar Akt/forkhead signaling axis in cardiac myocytes in vitro and in vivo, which is regulated by insulin, insulin-like growth factor (IGF), stretch, pressure overload, and angiotensin II stimulation. FOXO3a gene transfer prevented both IGF and stretch-induced hypertrophy in rat neonatal cardiac myocyte cultures in vitro. Transduction with FOXO3a also caused a significant reduction in cardiomyocyte size in mouse hearts in vivo. Akt/FOXO signaling regulated the expression of multiple atrophy-related genes “atrogenes,” including the ubiquitin ligase atrogin-1 (MAFbx). In cardiac myocyte cultures, transduction with constitutively active Akt or treatment with IGF suppressed atrogin-1 mRNA expression, whereas transduction with FOXO3a stimulated its expression. FOXO3a transduction activated the atrogin-1 promoter in both cultured myocytes and mouse heart. Thus, in cardiomyocytes, as in skeletal muscle, FOXO3a activates an atrogene transcriptional program, which retards or prevents hypertrophy and is down-regulated by multiple physiological and pathological stimuli of myocyte growth.

[1]  A Celentano,et al.  Cardiac abnormalities in young women with anorexia nervosa. , 1994, British heart journal.

[2]  G. Thomas,et al.  TOR signalling and control of cell growth. , 1997, Current opinion in cell biology.

[3]  M. Birnbaum,et al.  Regulation of Angiogenesis by Glycogen Synthase Kinase-3β* , 2002, The Journal of Biological Chemistry.

[4]  Hiroyuki Aburatani,et al.  Skeletal Muscle FOXO1 (FKHR) Transgenic Mice Have Less Skeletal Muscle Mass, Down-regulated Type I (Slow Twitch/Red Muscle) Fiber Genes, and Impaired Glycemic Control*[boxs] , 2004, Journal of Biological Chemistry.

[5]  J. Papadimitriou,et al.  Regression of Left Ventricular Dilation and Hypertrophy after Removal of Volume Overload: Morphological and Ultrastructural Study , 1974, Circulation research.

[6]  Yi-Ping Li,et al.  Atrophic Remodeling of the Heart In Vivo Simultaneously Activates Pathways of Protein Synthesis and Degradation , 2003, Circulation.

[7]  G. Yancopoulos,et al.  The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. , 2004, Molecular cell.

[8]  A. Goldberg,et al.  Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Stephen J. Elledge,et al.  SKP1 Connects Cell Cycle Regulators to the Ubiquitin Proteolysis Machinery through a Novel Motif, the F-Box , 1996, Cell.

[10]  P. Kang,et al.  Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Hasselgren,et al.  Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle. , 2003, The international journal of biochemistry & cell biology.

[12]  R. Zhao,et al.  Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity , 2005, Oncogene.

[13]  A. Hoeflich,et al.  IGF-binding protein-5: flexible player in the IGF system and effector on its own. , 2002, The Journal of endocrinology.

[14]  W. Cavenee,et al.  Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. , 1998, Genomics.

[15]  D J Glass,et al.  Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.

[16]  G. Shipley,et al.  Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy , 1998, Nature Medicine.

[17]  D. Cyr,et al.  CHIP Is a U-box-dependent E3 Ubiquitin Ligase , 2001, The Journal of Biological Chemistry.

[18]  P A Lachenbruch,et al.  Quantitative Changes in the Capillary Bed during Developing, Peak, and Stabilized Cardiac Hypertrophy in the Spontaneously Hypertensive Rat , 1982, Circulation research.

[19]  I. Shiojima,et al.  Akt Activity Negatively Regulates Phosphorylation of AMP-activated Protein Kinase in the Heart* , 2003, Journal of Biological Chemistry.

[20]  G. Fishman,et al.  Conditional transgene expression in the heart. , 1996, Circulation research.

[21]  R. Kitsis,et al.  Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. , 2000, Circulation.

[22]  S. Cook,et al.  Phenotypic Spectrum Caused by Transgenic Overexpression of Activated Akt in the Heart* , 2002, The Journal of Biological Chemistry.

[23]  J. Testa,et al.  Cell Cycle Withdrawal Promotes Myogenic Induction of Akt, a Positive Modulator of Myocyte Survival , 1999, Molecular and Cellular Biology.

[24]  Marco Sandri,et al.  Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.

[25]  C. Kahn,et al.  Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways , 2002, Cell.

[26]  K. Chien,et al.  Signaling pathways for cardiac hypertrophy and failure. , 1999, The New England journal of medicine.

[27]  W. Aird,et al.  The Akt-regulated Forkhead Transcription Factor FOXO3a Controls Endothelial Cell Viability through Modulation of the Caspase-8 Inhibitor FLIP* , 2004, Journal of Biological Chemistry.

[28]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[29]  A. Banes,et al.  A new vacuum-operated stress-providing instrument that applies static or variable duration cyclic tension or compression to cells in vitro. , 1985, Journal of cell science.

[30]  J. Balligand,et al.  Endogenous nitric oxide mechanisms mediate the stretch dependence of Ca2+ release in cardiomyocytes , 2001, Nature Cell Biology.

[31]  S. Kihara,et al.  Adiponectin-mediated modulation of hypertrophic signals in the heart , 2004, Nature Medicine.

[32]  M. Nieminen,et al.  Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.

[33]  K. Nakayama,et al.  U Box Proteins as a New Family of Ubiquitin-Protein Ligases* , 2001, The Journal of Biological Chemistry.

[34]  Jian Xu,et al.  Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy , 2004, Circulation research.

[35]  A. Goldberg,et al.  Patterns of gene expression in atrophying skeletal muscles: response to food deprivation , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  A. Kuroiwa,et al.  Weight reduction regresses left ventricular mass regardless of blood pressure level in obese subjects. , 1996, American heart journal.

[37]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[38]  D. Accili,et al.  FoxOs at the Crossroads of Cellular Metabolism, Differentiation, and Transformation , 2004, Cell.

[39]  M. Birnbaum,et al.  Akt1/PKBα Is Required for Normal Growth but Dispensable for Maintenance of Glucose Homeostasis in Mice* , 2001, The Journal of Biological Chemistry.

[40]  L. Kirshenbaum,et al.  Suppression of Akt Signaling Induces Fas Ligand Expression: Involvement of Caspase and Jun Kinase Activation in Akt-Mediated Fas Ligand Regulation , 2002, Molecular and Cellular Biology.

[41]  J. Ross,et al.  Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  A. Goldberg,et al.  Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  P. Kang,et al.  The Insulin-like Growth Factor 1 Receptor Induces Physiological Heart Growth via the Phosphoinositide 3-Kinase(p110α) Pathway* , 2004, Journal of Biological Chemistry.

[44]  J. Woodgett,et al.  Glycogen Synthase Kinase-3β Is a Negative Regulator of Cardiomyocyte Hypertrophy , 2000, The Journal of cell biology.

[45]  A. Goldberg,et al.  Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. , 1996, The New England journal of medicine.

[46]  C. Kahn,et al.  Akt Signaling Mediates Postnatal Heart Growth in Response to Insulin and Nutritional Status* , 2002, The Journal of Biological Chemistry.

[47]  Luigi Fratta,et al.  Melusin, a muscle-specific integrin β1–interacting protein, is required to prevent cardiac failure in response to chronic pressure overload , 2003, Nature Medicine.

[48]  P. Sugden Ras, Akt, and Mechanotransduction in the Cardiac Myocyte , 2003, Circulation research.

[49]  S. Elledge,et al.  Structure of the Cul1–Rbx1–Skp1–F boxSkp2 SCF ubiquitin ligase complex , 2002, Nature.

[50]  Y. Ahn,et al.  Nuclear Targeting of Akt Enhances Kinase Activity and Survival of Cardiomyocytes , 2003, Circulation research.

[51]  A. Mahfoudi,et al.  p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. , 1997, Genes & development.

[52]  A. Clerk,et al.  Regulation of cardiac myocyte protein synthesis through phosphatidylinositol 3' kinase and protein kinase B. , 2001, Advances in enzyme regulation.

[53]  N. Takahashi,et al.  Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. , 1995, The Journal of clinical investigation.

[54]  L. Velloso,et al.  Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart. , 1995, The Biochemical journal.

[55]  P. Kang,et al.  Akt/Protein Kinase B Promotes Organ Growth in Transgenic Mice , 2002, Molecular and Cellular Biology.

[56]  J. Molkentin,et al.  Calcineurin and cardiac hypertrophy: Where have we been? Where are we going? , 2002, The Journal of physiology.

[57]  S. Houser,et al.  Regression of cellular hypertrophy after left ventricular assist device support. , 1998, Circulation.